VICORE PHARMA ... idiopathic pulmonary fibrosis (IPF), systemic sclerosis (SSc), IPF cough ... Former

  • View
    0

  • Download
    0

Embed Size (px)

Text of VICORE PHARMA ... idiopathic pulmonary fibrosis (IPF), systemic sclerosis (SSc), IPF cough ......

  • VICORE PHARMA

    A Rare Disease Company with a Focus on Patients with Fibrotic Lung Disease

  • FORWARD LOOKING STATEMENT

    This presentation may contain certain forward-looking statements and forecasts based on uncertainty, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on Vicore Pharma’s business, financial condition and results of operations. The terms “anticipates”, “assumes”, “believes”, “can”, “could”, “estimates”, “expects”, “forecasts”, “intends”, “may”, “might”, “plans”, “should”, “projects”, “will”, “would” or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statement. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied in a forward- looking statement or affect the extent to which a particular projection is realized. Factors that could cause these differences include, but are not limited to, implementation of Vicore Pharma’s strategy and its ability to further grow, risks associated with the development and/or approval of Vicore Pharma’s products candidates, ongoing clinical trials and expected trial results, the ability to commercialize C21, technology changes and new products in Vicore Pharma’s potential market and industry, the ability to develop new products and enhance existing products, the impact of competition, changes in general economy and industry conditions and legislative, regulatory and political factors.

    No assurance can be given that such expectations will prove to have been correct. Vicore Pharma disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

    2

  • INVESTMENT CASE

     Fibrotic lung diseases – devastating with need of better therapies

     Two complementary programs for treatment of fibrotic lung disease • VP01 – C21 (new modality) in phase II • VP02 – IMiD (reformulated) entering phase I

     Differentiated programs addressing fibrosis, vasculopathy and cough – improving quality of life

     Diversification through two programs with multiple indications – idiopathic pulmonary fibrosis (IPF), systemic sclerosis (SSc), IPF cough

     Large market potential

     Highly experienced leadership

     Existing shareholders include HealthCap (28%), Robur, AP4, Handelsbanken and HBM Healthcare

  • Vicore is well positioned to develop novel therapies for fibrotic lung disease

  • THE TEAM

    First class drug development team

  • CARL-JOHAN DALSGAARD, CEO MD, PhD, Karolinska Institute with post-doc experience from Harvard Former Head of Therapy Area Pain Control, AstraZeneca R&D 10 years of experience from senior management, AstraZeneca 19 years of experience as Venture Partner at HealthCap

    OLA CAMBER, CMC MSc, PhD, Uppsala University Former Director Pharmaceutics & Biopharmaceuticals, Pharmacia Former Director Astra Zeneca, Pre-formulation & Biopharmaceuticals More than 30 years of experience in drug development

    KICKI JOHANSSON, HEAD OF DRUG DEVELOPMENT MSc Pharm, PhD Former Senior Project Leader/VP AstraZeneca Accountable for the development of over 40 new compounds Approximately 30 years’ experience of drug development

    JOHANNA GRÄNS, REGULATORY AFFAIRS MANAGER MSc, PhD, University of Gothenburg Extensive experience in preclinical R&D Research experience in drug metabolism

    HANS JEPPSSON, CFO PhD, Finance with post-doc research at UC Berkeley Cross-disciplinary background in finance and medicine Former equity research analyst at Danske Bank Professor in Finance at Gothenburg School of Economics and Law

    ROHIT BATTA, CMO MBBS, King’s College London, MFPM Medical doctor with extensive industry experience in Rare Diseases Joins us from GSK, where he led the global medical and clinical development of the world’s first paediatric gene therapy

    GÖRAN TORNLING, SENIOR MEDICAL ADVISOR MD, PhD, Karolinska Institutet Medical doctor and Pulmonologist with more than 20 years of clinical experience Former Director Clinical Strategy, AZ and responsible for IPF study designs

    JOHAN RAUD, CSO MD, PhD, Karolinska Institutet Former Director Inflammation research AstraZeneca Investment Manager KIF 25 years of experience in drug development

    THE VICORE TEAM

    6

    NINA CARLÈN, CHIEF ADMINISTRATIVE OFFICER Education from Berghs School of Communication More than 15 years of marketing and communications Responsible for HR and company administration

    CHRISTIAN HALL, INVESTOR RELATIONS MSc, Stockholm School of Economics Experience as sell side analyst at Swedbank IR consultant at Oxenstierna & Partners

    MINMI FLENSBURG; CLINICAL OPERATIONS DMV, PhD Experience from Novo, Lundbeck and several biotech companies Successfully leading drug candidates through phase I-IV

  • FIBROTIC LUNG DISEASE

    Rare diseases with large medical needs

  • IDIOPATHIC PULMONARY FIBROSIS (IPF) A rare interstitial pulmonary disease with unknown etiology High morbidity with shortness of breath and cough with a life expectancy of 3-5 years after diagnosis

    Two drugs on the market Esbriet and Ofev only slows disease progression and show significant side effects, despite that reached sales of $ 2.3 billon in 2018

    Prevalence US: 150,000 EU: 100,000 Male>female

  • IPF COUGH A dry persistent cough In IPF a severe debilitating cough correlates to disease progression, morbidity and mortality

    The pictures below shows a herniated diaphragm due to IPF cough

    Prevalence for IPF with severe dry cough US: 60,000 EU: 40,000 Male>female

    Severe dry cough is the symptom that impacts quality of life the most Currently no therapy is available

    The IPF patient wants to feel better, stop coughing and live longer – in that order

  • SYSTEMIC SCLEROSIS (SSc)

    A rare autoimmune disease with heterogeneous clinical manifestations The disease is chronic and has frequently a progressive course, can affect every organ with significant disability, disfigurement and mortality

    Prevalence for severe disseminated disease with ILD US: 36,000 EU: 21,000 Female>male

    Treatment options Ofev (nintedanib) is recently approved for SSc/lung fibrosis (ILD)

  • PIPELINE

    Two phase II programs and one program with proven clinical efficacy

  • Fibrosis

    Exploratory Preclinical Phase I Phase II

    cv Systemic Sclerosis

    Idiopathic Pulmonary Fibrosis

    VICORE PIPELINE

    12

    VP01 (C21)

    VP02 (IMiD)

    FOLLOW-ON MOLECULES (AT2R)

    Idiopathic Pulmonary Fibrosis

  • VP01 (C21)

    First in class small molecule AT2R agonist

  • C21 MODE OF ACTION

    C21 is the first small molecule angiotensin II type 2 receptor (AT2R) agonist and also a low affinity thromboxane receptor (TP) antagonist

    C21 AT2R

    TP

    Antagonist Low affinity

    Agonist High affinity

    Antifibrotic

    Vasodilation

    Reduced platelet activation

    Anti-inflammatory

    C21 has dual mode of actions, both of which are relevant for IPF and SSc

    Counterbalance AT1R

  • AT2R EXPRESSION IN MAN

    According to the Human Protein Atlas, AT2R is primarily expressed in lung in healthy individuals

    8%

    0%

    4%

    6%

    2%

    10%

    IPF SScControl

    Total AT2r quantification In idiopathic systemic sclerosis (IPF) and systemic sclerosis (SSc), AT2R is dramatically upregulated suggesting a crucial role in counteracting fibrosis

    Parra 2014

    AT2R is expressed in human lung with a significant up-regulation in fibrotic disease

  • Wollin 2014 Heckmann 2016 Rathinasabapathy 2018

    Esbriet PamrevlumabOfev C21

    C21 IN THE BLEOMYCIN IPF MOUSE MODEL

    16

    Reduction of fibrosis score (∆ compared with placebo) when drugs are given as prevention

    -23% -38% -41%

    -65%

    PIRFENIDONE ROCHE

    50MG/KG

    NINTEDANIB B-I

    60MG/KG

    ANTI-CTGF FIBROGEN 30MG/KG 0.03MG/KG

    C21 effect is at least comparable to standard of care

    C21

    Esbriet PamrevlumabOfev

  • C-21 IN THE MONOCROTALINE PH MOUSE MODEL

    20

    10

    5

    0

    15

    100

    60

    40

    20

    80

    4

    2

    1

    0

    3

    4

    2

    1

    0

    3

    % Interstitial Lung Fibrosis

    Right Ventricular systolic pressure

    Relative AT2 Receptor Expression

    Relative TGF-β Gene Expression

    Representative images of lung fibrosis

    C21 reverses cardiopulmonary fibrosis and reduce PH

  • C21 IS ALSO A TP-RECEPTOR ANTAGONIST

    In addition to the NO-mediated vasodilation via AT2R C21 also exhibit an AT2R independent vasodilation in human resistance vessels via the thromboxane receptor

    C21 can address vasculopathy through both AT2R and TP receptor

    Vicore, data on file

  • VP01 – STATUS

    Preclinical Efficacy

    Strong effects in models of IPF and pulmonary hypertension Reduce expression of profibrotic growth factors Dilates small resistance vess